Bank of Montreal Can Buys Shares of 42,398 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Bank of Montreal Can bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 42,398 shares of the biotechnology company’s stock, valued at approximately $329,000.

Other large investors also recently added to or reduced their stakes in the company. State of New Jersey Common Pension Fund D lifted its stake in shares of BioCryst Pharmaceuticals by 21.9% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 289,701 shares of the biotechnology company’s stock valued at $2,039,000 after purchasing an additional 52,086 shares during the last quarter. Inspire Investing LLC lifted its stake in shares of BioCryst Pharmaceuticals by 37.8% in the 2nd quarter. Inspire Investing LLC now owns 44,583 shares of the biotechnology company’s stock valued at $314,000 after purchasing an additional 12,234 shares during the last quarter. First Republic Investment Management Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 147.5% in the 2nd quarter. First Republic Investment Management Inc. now owns 29,294 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 17,457 shares during the last quarter. Empire Financial Management Company LLC lifted its stake in shares of BioCryst Pharmaceuticals by 41.7% in the 2nd quarter. Empire Financial Management Company LLC now owns 42,500 shares of the biotechnology company’s stock valued at $299,000 after purchasing an additional 12,500 shares during the last quarter. Finally, Ballentine Partners LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at $77,000. 91.46% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $5.35 on Monday. The stock has a 50-day simple moving average of $6.20 and a 200-day simple moving average of $7.09. The stock has a market capitalization of $1.10 billion, a PE ratio of -4.28 and a beta of 1.92. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.82 and a 1 year high of $13.49.

Analyst Ratings Changes

Several equities analysts have recently commented on BCRX shares. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, August 4th. StockNews.com assumed coverage on BioCryst Pharmaceuticals in a research note on Thursday, October 5th. They set a “hold” rating on the stock. Needham & Company LLC reissued a “buy” rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday, November 6th. Jefferies Financial Group raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Friday, August 4th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday, September 25th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.63.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.